Amica Retiree Medical Trust’s Lam Research LRCX Stock Holding History

Amica Retiree Medical Trust’s Portfolio LRCX Stock Details LRCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$769K	Sell	5,741 -1,031	-15%	-$109K	1.05%	27
2025 Q2	$659K	Hold	6,772	–	–	0.95%	32
2025 Q1	$492K	Sell	6,772 -346	-5%	-$27.2K	0.75%	44
2024 Q4	$514K	Sell	7,118 -622	-8%	-$47.2K	0.49%	55
2024 Q3	$632K	Buy	+7,740	New	+$673K	0.52%	52
2023 Q3	$743K	Hold	11,850	–	–	0.87%	41
2023 Q2	$762K	Sell	11,850 -6,720	-36%	-$379K	0.85%	45
2023 Q1	$984K	Buy	18,570 +6,440	+53%	+$316K	1.04%	33
2022 Q4	$510K	Sell	12,130 -12,430	-51%	-$520K	0.66%	54
2022 Q3	$899K	Sell	24,560 -2,110	-8%	-$93.9K	1.12%	28
2022 Q2	$1.14M	Buy	26,670 +1,000	+4%	+$47.6K	1.29%	22
2022 Q1	$1.38M	Buy	25,670 +1,500	+6%	+$87.3K	1.29%	17
2021 Q4	$1.74M	Hold	24,170	–	–	1.48%	13
2021 Q3	$1.38M	Sell	24,170 -5,450	-18%	-$332K	1.24%	18
2021 Q2	$1.93M	Sell	29,620 -4,580	-13%	-$289K	1.22%	19
2021 Q1	$2.04M	Hold	34,200	–	–	1.38%	15
2020 Q4	$1.61M	Buy	34,200 +12,110	+55%	+$509K	1.14%	19
2020 Q3	$733K	Buy	22,090 +2,830	+15%	+$97.5K	0.57%	49
2020 Q2	$623K	Hold	19,260	–	–	0.49%	61
2020 Q1	$462K	Buy	19,260 +12,490	+184%	+$360K	0.41%	69
2019 Q4	$198K	Hold	6,770	–	–	0.15%	208
2019 Q3	$156K	Sell	6,770 -6,740	-50%	-$142K	0.12%	230
2019 Q2	$254K	Hold	13,510	–	–	0.21%	132
2019 Q1	$242K	Hold	13,510	–	–	0.21%	141
2018 Q4	$184K	Hold	13,510	–	–	0.18%	165
2018 Q3	$205K	Hold	13,510	–	–	0.17%	164
2018 Q2	$234K	Hold	13,510	–	–	0.2%	141
2018 Q1	$274K	Hold	13,510	–	–	0.24%	134
2017 Q4	$249K	Hold	13,510	–	–	0.19%	151
2017 Q3	$250K	Hold	13,510	–	–	0.2%	147
2017 Q2	$191K	Hold	13,510	–	–	0.16%	177
2017 Q1	$173K	Hold	13,510	–	–	0.14%	193
2016 Q4	$143K	Hold	13,510	–	–	0.11%	220
2016 Q3	$128K	Hold	13,510	–	–	0.11%	226
2016 Q2	$114K	Hold	13,510	–	–	0.1%	238
2016 Q1	$112K	Hold	13,510	–	–	0.1%	231
2015 Q4	$107K	Hold	13,510	–	–	0.09%	238
2015 Q3	$88K	Hold	13,510	–	–	0.08%	257
2015 Q2	$110K	Hold	13,510	–	–	0.09%	240
2015 Q1	$95K	Hold	13,510	–	–	0.08%	251
2014 Q4	$107K	Hold	13,510	–	–	0.09%	239
2014 Q3	$101K	Hold	13,510	–	–	0.09%	240
2014 Q2	$91K	Hold	13,510	–	–	0.08%	247
2014 Q1	$74K	Hold	13,510	–	–	0.06%	258
2013 Q4	$74K	Buy	+13,510	New	+$71.1K	0.06%	252

Other funds holding LRCX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amica Retiree Medical Trust's LRCX Position: Q3 2025 in Review

Amica Retiree Medical Trust reduced its Lam Research (LRCX) stake by 15% in Q3 2025, selling an estimated $109K and leaving 5,741 shares worth $769K. The position accounts for 1.05% of the portfolio, ranked #27.

Amica Retiree Medical Trust first reported a position in LRCX in Q4 2013 and has held it in 45 quarters since. The position peaked at $2.04M in Q1 2021. 2,108 funds tracked by Wall St. Rank hold LRCX as of Q3 2025.

Amica Retiree Medical Trust held 5,741 shares of Lam Research worth $769K as of Q3 2025.
Amica Retiree Medical Trust sold 1,031 Lam Research shares in Q3 2025, an estimated $109K.
Lam Research made up 1.05% of Amica Retiree Medical Trust's portfolio in Q3 2025, its #27 holding.
Amica Retiree Medical Trust first reported a position in Lam Research in Q4 2013 and has held it in 45 quarters since.
Amica Retiree Medical Trust's Lam Research position peaked at $2.04M in Q1 2021.
2,108 funds tracked by Wall St. Rank held Lam Research as of Q3 2025.

Based on Amica Retiree Medical Trust's 13F filing for Q3 2025, filed 7 Nov 2025.